Figure 4
Figure 4. EMSA using recombinant RUNX1 protein and oligonucleotide probes with RUNX1 binding sites. (A) RUNX1 protein binding to probe containing sites I and II (−680/−660 base pairs [bp]): lane 1, probe alone; lane 2, protein binding to Wt probe; lane 3, loss of binding with excess unlabeled Wt probe; lane 4, no loss of binding with normal IgG; lane 5, supershift with anti-RUNX1 antibody. (B) Binding to Wt probe containing RUNX1 site III (−643/−638 bp): lane 1, probe alone; lane 2, protein binding to the probe; lane 3, loss of binding with excess unlabeled probe; lane 4, no loss of binding with normal IgG; lane 5, supershift with anti-RUNX1 antibody. (C) Binding to probe containing RUNX1 site IV (−601/−595); lane 1, probe alone; lane 2, protein binding to probe; lane 3, loss of binding with excess unlabeled probe; lane 4, supershift with anti-RUNX1 antibody; lane 5, no loss of binding with normal IgG.

EMSA using recombinant RUNX1 protein and oligonucleotide probes with RUNX1 binding sites. (A) RUNX1 protein binding to probe containing sites I and II (−680/−660 base pairs [bp]): lane 1, probe alone; lane 2, protein binding to Wt probe; lane 3, loss of binding with excess unlabeled Wt probe; lane 4, no loss of binding with normal IgG; lane 5, supershift with anti-RUNX1 antibody. (B) Binding to Wt probe containing RUNX1 site III (−643/−638 bp): lane 1, probe alone; lane 2, protein binding to the probe; lane 3, loss of binding with excess unlabeled probe; lane 4, no loss of binding with normal IgG; lane 5, supershift with anti-RUNX1 antibody. (C) Binding to probe containing RUNX1 site IV (−601/−595); lane 1, probe alone; lane 2, protein binding to probe; lane 3, loss of binding with excess unlabeled probe; lane 4, supershift with anti-RUNX1 antibody; lane 5, no loss of binding with normal IgG.

Close Modal

or Create an Account

Close Modal
Close Modal